Cargando…
HLA-A*02:07 Is a Protective Allele for EBV Negative and a Susceptibility Allele for EBV Positive Classical Hodgkin Lymphoma in China
HLA-A2 protects from EBV+ classical Hodgkin lymphoma (cHL) in Western Europe, but it is unknown whether this protective effect also exists in the Chinese population. We investigated the association of HLA-A2 and specific common and well documented HLA-A2 subtypes with EBV stratified cHL patients (n ...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280205/ https://www.ncbi.nlm.nih.gov/pubmed/22355400 http://dx.doi.org/10.1371/journal.pone.0031865 |
_version_ | 1782223790561820672 |
---|---|
author | Huang, Xin Hepkema, Bouke Nolte, Ilja Kushekhar, Kushi Jongsma, Theo Veenstra, Rianne Poppema, Sibrand Gao, Zifen Visser, Lydia Diepstra, Arjan van den Berg, Anke |
author_facet | Huang, Xin Hepkema, Bouke Nolte, Ilja Kushekhar, Kushi Jongsma, Theo Veenstra, Rianne Poppema, Sibrand Gao, Zifen Visser, Lydia Diepstra, Arjan van den Berg, Anke |
author_sort | Huang, Xin |
collection | PubMed |
description | HLA-A2 protects from EBV+ classical Hodgkin lymphoma (cHL) in Western Europe, but it is unknown whether this protective effect also exists in the Chinese population. We investigated the association of HLA-A2 and specific common and well documented HLA-A2 subtypes with EBV stratified cHL patients (n = 161) from the northern part of China. Quantitative-PCR and sequence-based subtyping was performed to identify HLA-A2 positive samples and their subtypes. 67 (42%) of the cHL patients were EBV+. There were no significant differences in percentages of HLA-A2 positivity between cHL and controls (65% vs 66%) and between EBV+ and EBV− cHL patients (70% vs 61%). The frequency distribution of HLA-A2 subtypes was significantly different between EBV stratified cHL subgroups and controls. This difference was most striking for the HLA-A*02:07 type with a frequency of 38% in EBV+ cHL, 8% in EBV− cHL and 20% in controls. Significant differences were also observed for the HLA-A*02:07, HLA-A2 (non-02:07) and the A2-negative typings between EBV+ cHL vs controls (p = 0.028), EBV− cHL vs controls (p = 0.045) and EBV+ vs EBV− cHL cases (p = 2×10(−5)). In conclusion, HLA-A*02:07 is a predisposing allele for EBV+ cHL and a protective allele for EBV− cHL in the northern Chinese population. |
format | Online Article Text |
id | pubmed-3280205 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-32802052012-02-21 HLA-A*02:07 Is a Protective Allele for EBV Negative and a Susceptibility Allele for EBV Positive Classical Hodgkin Lymphoma in China Huang, Xin Hepkema, Bouke Nolte, Ilja Kushekhar, Kushi Jongsma, Theo Veenstra, Rianne Poppema, Sibrand Gao, Zifen Visser, Lydia Diepstra, Arjan van den Berg, Anke PLoS One Research Article HLA-A2 protects from EBV+ classical Hodgkin lymphoma (cHL) in Western Europe, but it is unknown whether this protective effect also exists in the Chinese population. We investigated the association of HLA-A2 and specific common and well documented HLA-A2 subtypes with EBV stratified cHL patients (n = 161) from the northern part of China. Quantitative-PCR and sequence-based subtyping was performed to identify HLA-A2 positive samples and their subtypes. 67 (42%) of the cHL patients were EBV+. There were no significant differences in percentages of HLA-A2 positivity between cHL and controls (65% vs 66%) and between EBV+ and EBV− cHL patients (70% vs 61%). The frequency distribution of HLA-A2 subtypes was significantly different between EBV stratified cHL subgroups and controls. This difference was most striking for the HLA-A*02:07 type with a frequency of 38% in EBV+ cHL, 8% in EBV− cHL and 20% in controls. Significant differences were also observed for the HLA-A*02:07, HLA-A2 (non-02:07) and the A2-negative typings between EBV+ cHL vs controls (p = 0.028), EBV− cHL vs controls (p = 0.045) and EBV+ vs EBV− cHL cases (p = 2×10(−5)). In conclusion, HLA-A*02:07 is a predisposing allele for EBV+ cHL and a protective allele for EBV− cHL in the northern Chinese population. Public Library of Science 2012-02-15 /pmc/articles/PMC3280205/ /pubmed/22355400 http://dx.doi.org/10.1371/journal.pone.0031865 Text en Huang et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Huang, Xin Hepkema, Bouke Nolte, Ilja Kushekhar, Kushi Jongsma, Theo Veenstra, Rianne Poppema, Sibrand Gao, Zifen Visser, Lydia Diepstra, Arjan van den Berg, Anke HLA-A*02:07 Is a Protective Allele for EBV Negative and a Susceptibility Allele for EBV Positive Classical Hodgkin Lymphoma in China |
title | HLA-A*02:07 Is a Protective Allele for EBV Negative and a Susceptibility Allele for EBV Positive Classical Hodgkin Lymphoma in China |
title_full | HLA-A*02:07 Is a Protective Allele for EBV Negative and a Susceptibility Allele for EBV Positive Classical Hodgkin Lymphoma in China |
title_fullStr | HLA-A*02:07 Is a Protective Allele for EBV Negative and a Susceptibility Allele for EBV Positive Classical Hodgkin Lymphoma in China |
title_full_unstemmed | HLA-A*02:07 Is a Protective Allele for EBV Negative and a Susceptibility Allele for EBV Positive Classical Hodgkin Lymphoma in China |
title_short | HLA-A*02:07 Is a Protective Allele for EBV Negative and a Susceptibility Allele for EBV Positive Classical Hodgkin Lymphoma in China |
title_sort | hla-a*02:07 is a protective allele for ebv negative and a susceptibility allele for ebv positive classical hodgkin lymphoma in china |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280205/ https://www.ncbi.nlm.nih.gov/pubmed/22355400 http://dx.doi.org/10.1371/journal.pone.0031865 |
work_keys_str_mv | AT huangxin hlaa0207isaprotectivealleleforebvnegativeandasusceptibilityalleleforebvpositiveclassicalhodgkinlymphomainchina AT hepkemabouke hlaa0207isaprotectivealleleforebvnegativeandasusceptibilityalleleforebvpositiveclassicalhodgkinlymphomainchina AT nolteilja hlaa0207isaprotectivealleleforebvnegativeandasusceptibilityalleleforebvpositiveclassicalhodgkinlymphomainchina AT kushekharkushi hlaa0207isaprotectivealleleforebvnegativeandasusceptibilityalleleforebvpositiveclassicalhodgkinlymphomainchina AT jongsmatheo hlaa0207isaprotectivealleleforebvnegativeandasusceptibilityalleleforebvpositiveclassicalhodgkinlymphomainchina AT veenstrarianne hlaa0207isaprotectivealleleforebvnegativeandasusceptibilityalleleforebvpositiveclassicalhodgkinlymphomainchina AT poppemasibrand hlaa0207isaprotectivealleleforebvnegativeandasusceptibilityalleleforebvpositiveclassicalhodgkinlymphomainchina AT gaozifen hlaa0207isaprotectivealleleforebvnegativeandasusceptibilityalleleforebvpositiveclassicalhodgkinlymphomainchina AT visserlydia hlaa0207isaprotectivealleleforebvnegativeandasusceptibilityalleleforebvpositiveclassicalhodgkinlymphomainchina AT diepstraarjan hlaa0207isaprotectivealleleforebvnegativeandasusceptibilityalleleforebvpositiveclassicalhodgkinlymphomainchina AT vandenberganke hlaa0207isaprotectivealleleforebvnegativeandasusceptibilityalleleforebvpositiveclassicalhodgkinlymphomainchina |